Loading...
XKRX
003120
Market cap107mUSD
Dec 05, Last price  
23,300.00KRW
1D
-0.64%
1Q
-5.67%
Jan 2017
-5.28%
Name

Ilsung Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XKRX:003120 chart
P/E
12.13
P/S
2.30
EPS
1,921.18
Div Yield, %
—
Shrs. gr., 5y
-0.29%
Rev. gr., 5y
7.35%
Revenues
69.02b
-11.58%
78,833,528,00079,870,404,00071,467,214,00068,594,693,00068,191,775,02077,160,760,62062,807,489,69062,828,920,56061,745,116,14067,463,384,16067,043,035,12061,652,595,25048,411,627,88040,600,732,25042,089,835,82061,247,846,53078,053,232,12069,018,341,000
Net income
13.09b
P
17,699,848,00034,163,059,0008,049,787,0006,297,465,00035,083,007,47036,451,736,0807,955,018,2804,034,563,91098,853,930,9303,017,242,0402,628,652,9302,945,528,7406,718,550,3603,220,256,800-1,367,510,420108,669,345,880-20,940,893,24713,094,107,000
CFO
-4.26b
L-89.74%
4,171,398,00016,535,708,0001,265,121,00018,644,306,0008,244,202,610-11,318,601,8705,063,947,6204,190,571,1006,041,134,630-31,013,469,62010,158,675,33015,091,217,1604,388,672,7101,557,299,4605,704,073,470-38,966,011,120-41,474,992,530-4,255,830,000
Dividend
Dec 27, 20231500 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ilsung Pharmaceuticals Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, anti-coagulants, circulatory system drugs, contrast agents, diabetes treatments, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, anesthetics, antipyretics, and cardiovascular system products. Ilsung Pharmaceuticals Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
URL
https://www.ilsung-ph.co.kr
IPO date
Jan 14, 1985
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT